Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2327 · 1 trial · 1 indication
Hamilton Rating Scale for Depression (HAM-D)is a 17-item, clinician-rated scale that assesses depressive symptoms. The HAMD-17 consists of 17 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent. The HAMD-17 total score is calculated as the sum of the 17 individual symptom scores; the total score can range from 0 to 52. Higher HAMD-17 scores indicate more severe depression.
The Hamilton Rating Scale for Anxiety (HAM-A) is used as a rating measure of anxiety severity. The scale consists of 14 items. Each item is rated on a scale of 0 to 4. The HAM-A total score is the sum of the 14 items and the score ranges from 0 to 56, 0 is considered the best outcome.
| Arm | Type | Description |
|---|---|---|
| AZD2327 | EXPERIMENTAL | AZD2327 3mg BID |
| Placebo | PLACEBO_COMPARATOR | Placebo BID |
| Name | Type | Description |
|---|---|---|
| AZD2327 | DRUG | Tablet, Oral, Daily |
| Placebo | DRUG | Tablet, Oral, Daily |
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures * Diagnosis of major depressive disorder without psychotic features (MDD) Exclusion Criteria: * A history of substance or alcohol abuse within the past 6 months or dependence within 1 year of enrollment as ...
AZD2327 is an investigational small molecule being studied for the treatment of Anxious Major Depressive Disorder (AMDD). It was evaluated in a Phase 2 clinical trial as a potential antidepressant for this condition. The drug is not approved and remains in clinical development.
AZD2327 is described as a selective, high affinity enkephalinergic agonist. It acts on the enkephalinergic system, which is involved in modulating mood and stress responses. This mechanism was studied for its potential antidepressant effects in Anxious Major Depressive Disorder.
AZD2327 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company conducted a Phase 2 clinical trial to evaluate the drug's efficacy in patients with Anxious Major Depressive Disorder.
AZD2327 is in Phase 2 clinical development. A Phase 2 trial has been completed, but the drug is still investigational and has not received regulatory approval. Its development status reflects an ongoing evaluation of its safety and efficacy for Anxious Major Depressive Disorder.
AZD2327 has one completed clinical trial registered as NCT00759395, titled 'Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)'. This Phase 2 study enrolled 22 participants in the United States and was placebo-controlled, randomized, and double-blind.
AZD2327 is characterized as a selective, high affinity enkephalinergic agonist, meaning it activates the enkephalinergic system. This mechanism was the focus of its Phase 2 trial for Anxious Major Depressive Disorder. No other alternative names for the drug have been reported.